News Releases | Subscribe

June 27, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

Validation Study Shows Prolaris Test Identifies Men Who May Benefit from Surgery or Radiation at the Time of a Prostate Cancer Diagnosis SALT LAKE CITY, June 27, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of

Read More

June 25, 2019

Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first

Read More

June 19, 2019

Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan

BRACAnalysis Is Now Indicated as a Companion Diagnostic for Lynparza® (olaparib) in Women with Ovarian Cancer SALT LAKE CITY, June 19, 2019 (GLOBE NEWSWIRE) -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced the Japanese Ministry

Read More

May 7, 2019

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in personalized medicine, today

Read More

May 1, 2019

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer, will present at the Bank of

Read More

April 23, 2019

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

June 5, 2019

Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

SALT LAKE CITY, June 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 11:40 a.m.

Read More

May 1, 2019

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer, will present at the Bank of

Read More

April 23, 2019

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

June 27, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

Validation Study Shows Prolaris Test Identifies Men Who May Benefit from Surgery or Radiation at the Time of a Prostate Cancer Diagnosis SALT LAKE CITY, June 27, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of

Read More

June 25, 2019

Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first

Read More

June 19, 2019

Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan

BRACAnalysis Is Now Indicated as a Companion Diagnostic for Lynparza® (olaparib) in Women with Ovarian Cancer SALT LAKE CITY, June 19, 2019 (GLOBE NEWSWIRE) -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced the Japanese Ministry

Read More

June 27, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

Validation Study Shows Prolaris Test Identifies Men Who May Benefit from Surgery or Radiation at the Time of a Prostate Cancer Diagnosis SALT LAKE CITY, June 27, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of

Read More

June 3, 2019

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

SALT LAKE CITY, June 03, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two studies of the myRisk ® Hereditary Cancer test will be featured today in presentations at the annual meeting of

Read More

June 2, 2019

BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)

NCCN Guidelines Recommend Genetic Testing for All Patients with Pancreatic Cancer SALT LAKE CITY, June 02, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its BRACAnalysis CDx ® companion diagnostic test effectively identified

Read More

Myriad Corporate Presentation
Fact Sheet
Company Milestones